Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
| Autor: | Kevin F. Gibson, Imre Noth, Kevin R. Flaherty, Katia Rothhaar, Michael J. Klemsz, Sarah Frye, Terrence Chew, Naftali Kaminski, Wade Lange, David S. Wilkes |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Pathology Vital capacity Vital Capacity Administration Oral Placebo Gastroenterology Cohort Studies Idiopathic pulmonary fibrosis Internal medicine Humans Medicine Dosing Adverse effect Lung Serum Albumin Aged business.industry Complement C1q Middle Aged respiratory system medicine.disease Idiopathic Pulmonary Fibrosis Respiratory Function Tests respiratory tract diseases Clinical trial Matrix Metalloproteinase 7 Cohort Female Immunotherapy Patient Safety business Collagen Type V Biomarkers Cohort study |
| Zdroj: | European Respiratory Journal. 45:1393-1402 |
| ISSN: | 1399-3003 0903-1936 |
| DOI: | 10.1183/09031936.00105314 |
| Popis: | Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. IPF appears to be heterogeneous in pathobiology with ∼40% of IPF patients found to have elevated levels of circulating antibodies to the autoantigen type V collagen (col(V)).Following a targeted, precision medicine approach, we conducted a phase 1 study to test the safety and explore potential efficacy of IW001, a col(V) oral immunotherapeutic developed to treat antibody-positive IPF patients. We divided 30 antibody-positive IPF patients into three cohorts for daily dosing over a 24-week period.All patients completed treatment without serious adverse events, acute exacerbations or IPF-related hospitalisations. A decline in lung function occurred in the lowest-dose cohort that was comparable to that reported in placebo arms of published IPF trials. In contrast, the highest-dose cohort showed a trend toward stabilisation of forced vital capacity and matrix metalloproteinase 7, and a reduction in binding of C1q to anti-col(V) antibodies.IW001 may modulate the immune response to col(V) and may represent a new therapeutic for col(V)- reactive IPF patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|